SAR 113244

Drug Profile

SAR 113244

Alternative Names: SAR113244

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi
  • Class Monoclonal antibodies
  • Mechanism of Action CXCR5-receptor-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in France (SC, Injection)
  • 02 Jun 2016 Sanofi terminates a phase I trial in Systemic lupus erythematosus in Germany prior to enrolment(NCT02331810)
  • 01 Mar 2016 Sanofi completes a phase I trial for Systemic lupus erythematosus in Germany (NCT02321709)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top